LiveStay informed about what's happening at Nova
#drugR&D #insilicomedicine #systemsbiology #biomodeling #machinelearning
to accelerate the clinical development of drug candidate EYP001.
October 2, 2017
Watershed moment for in silico clinical trials as the FDA receives formal congressional requirement to apply in silico for the evaluation of new drugs.
In the presence of Mme Françoise Grossetête, Member of the European Parliament & Dr Adriano Henney, Secretary General of Avicenna Alliance.
The Avicenna Alliance has claimed a major victory in the revised EMA Regulation with the introduction of new text supporting modeling and simulation and predictive medicine in medicinal product development
It is now important for the European Medicines Agency to recognize and integrate into its regulatory processes these new methods of in silico simulation and prediction.
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.
Specify the optimal duration which helps to obtain the target effect, the dose that has to be used to maximize this effect. In other words, it’s to help us do the operations that are done today by a rather theoretical approach.
With the help of in silico models we can integrate the right patients in clinical trials and reduce the size of these trials.